Retevmo (selpercatinib) is a new advanced oncology product from Eli Lilly
Retevmo (selpercatinib) is a new advanced oncology product from Eli Lilly
… Eli Lilly Expands Oncology Therapy Portfolio With FDA Retevmo Approval …

LILLY SCORES ONCOLOGY TRIFECTA WITH RETEVMO FDA APPROVAL

Eli Lilly’s acquisition of Loxo Oncology pays off

John G. Baresky

Eli Lilly’s (NYSE: LLY) Retevmo (selpercatinib) has earned FDA approval. Retevmo was designated as a breakthrough therapy and evaluated according to the FDA’s priority review process. It is indicated for the:

  • Treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
  • Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy
  • Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)

Retevmo is a selective RET kinase inhibitor

Three FDA-approved indications is a win for cancer patients, oncologists and Lilly

The three indications also provide improved market access for Retevmo. Lilly will be able to position the product more effectively on managed care organization (MCO) and pharmacy benefit management (PBM) formularies as well as with specialty pharmacy providers.

Lilly cashing in its multi-billion purchase of Loxo -will Pfizer benefit as well?

Loxo initiated the development and commercialization of Retevmo by acquiring it and its other FDA approved oncology drug, Vitrakvi (larotrectinib), from Array Biopharma. The deal included royalties on presumptive global net sales of the pipeline candidates following approval by regulators and subsequent market launches. How those royalties will be issued moving forward is an interesting consideration as Array Biopharma was acquired by Pfizer in 2019 for about $10.6 billion.

Lilly is a growing contender in the development of novel cancer treatments

Thank you for reading this story

Read my other articles about medical and healthcare business trends, content marketing and digital strategy, brand and product management, consumer wellness, managed care and market access strategy. Contact me today for your healthcare content writing and content strategy needs.

I have over 20 years of experience in the healthcare industry producing valuable healthcare content for audiences and customers spanning physicians, nurses, pharmacists plus pharmaceutical companies, medical technology manufacturers, healthcare provider organizations, managed care, investors, consumers and other stakeholders.

Visit and connect…

LinkedIn

Portfolio

Twitter

Google My Business

As a healthcare content writer, my work aligns with an organization’s voice, brand, SEO elements, marketplace and objectives. It establishes trust in their company and recognized value in its products and services that generates revenue.

This experience was earned through working at Walgreens, Pfizer, AbelsonTaylor, TAP (Takeda Abbott Partnership), Hospira Worldwide and Boston Software Systems. ​

To a large degree, my professional interests emulate my family which includes doctors, nurses, physician assistants and other clinicians plus those that are working in healthcare administration and commercial enterprises.

Written by

Authentic, fact-based healthcare content marketing writing for medical, business, academic, patient and consumer audiences https://www.BareSkyMarketing.com/

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store